ReviewFrontiers in nutrition2025
The DASH diet in diabetes related complications or comorbidities: an unexpected friend.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dietary approaches to stop hypertension (DASH) in relation to hyper-triglyceridemic-waist (HTGW) phenotype in Iranian adults.Scientific reports · 2026Article
- Low-Grade Chronic Inflammation and Atherosclerotic Cardiovascular Risk: The Beneficial Role of Specific Nutritional Approaches.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global epidemic of diabetes and its complications poses a serious challenge to public health. Metabolic disorders and chronic hyperglycemia drive multi-system damage. The application of Dietary Approaches to Stop Hypertension (DASH) diet has been extended from hypertension management to multi-dimensional integrated prevention and treatment of diabetes. DASH diet significantly reduces the risk of type 2 diabetes by optimizing blood glucose homeostasis, reducing hemoglobin A1c (HbA1c), improving insulin sensitivity and insulin resistance, regulating lipid metabolism, and inhibiting oxidative stress and inflammation. In terms of management of complications, the DASH diet reduces the risk of diabetic nephropathy and delays decline of renal function. Its antihypertensive effect and improvement in arterial elasticity synergistically reduce the risk of cardiovascular events. The diet has also shown regulatory potential for metabolic abnormalities in polycystic ovary syndrome and microvascular damage in diabetic retinopathy. The DASH diet is suitable for long-term health management due to its advantages of standardized regimens and multi-target metabolic regulation. Future research needs to focus on molecular mechanisms, individual application optimization, and cross-disease synergies to strengthen the scientific basis and practical value in the comprehensive management of diabetes. This review discusses the multiple abilities by which the DASH diet provides comprehensive protection against diabetes and its complications or comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.